Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer

Ovarian cancer is the fifth leading cause of cancer-related female deaths. Due to serious side effects, relapse and resistance to standard chemotherapy, better and more targeted approaches are required. Mutation of the TP53 gene accounts for 50% of all human cancers. In the remaining malignancies, n...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanjirband, Maryam, Edmondson, Richard J., Lunec, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129997/
https://www.ncbi.nlm.nih.gov/pubmed/27223080
http://dx.doi.org/10.18632/oncotarget.9499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129997/
https://www.ncbi.nlm.nih.gov/pubmed/27223080
http://dx.doi.org/10.18632/oncotarget.9499

Ejemplares similares